Cargando…

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir

BACKGROUND: Patients with early stage prostate cancer have a variety of curative radiotherapy options, including conventionally-fractionated external beam radiotherapy (CF-EBRT) and hypofractionated stereotactic body radiotherapy (SBRT). Although results of CF-EBRT are well known, the use of SBRT fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anwar, Mekhail, Weinberg, Vivian, Chang, Albert J, Hsu, I-Chow, Roach, Mack, Gottschalk, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923240/ https://www.ncbi.nlm.nih.gov/pubmed/24484652 http://dx.doi.org/10.1186/1748-717X-9-42

Ejemplares similares

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA
por: Barra, Salvina, et al.
Publicado: (2014)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Extreme Hypofractionation with SBRT in Localized Prostate Cancer
por: Gómez-Aparicio, Maria Antonia, et al.
Publicado: (2021)

Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience
por: Murgic, Jure, et al.
Publicado: (2021)

Pre-plan parameters predict post-implant D(90) ≥ 140 Gy for (125)I permanent prostate implants
por: Alexander, Jes, et al.
Publicado: (2014)

Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT
por: Shen, Junyue, et al.
Publicado: (2021)

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap
por: Franca, Carlos Antônio da Silva, et al.
Publicado: (2014)

Comparative analysis of the prognosis of external beam radiation therapy (EBRT) and EBRT plus brachytherapy for glioblastoma multiforme: a SEER population-based study
por: Yang, Kai, et al.
Publicado: (2022)

The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
por: Sasaki, Takeshi, et al.
Publicado: (2018)

Hypofractionation Radiotherapy vs. Conventional Fractionation for Breast Cancer: A Comparative Review of Toxicity
por: Youssef, Ashraf, et al.
Publicado: (2018)

Radioresistance Mechanisms in Prostate Cancer Cell Lines Surviving Ultra-Hypo-Fractionated EBRT: Implications and Possible Clinical Applications
por: Sideri, Silvia, et al.
Publicado: (2022)

Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus ‘X’
por: Ahmed, Kamran A, et al.
Publicado: (2014)

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation
por: Repka, Michael C., et al.
Publicado: (2017)

Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis
por: Kim, Dong-Yun, et al.
Publicado: (2020)

PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure
por: Shah, T T, et al.
Publicado: (2016)

Predictive factors of (18)F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?
por: Johnson, Alison C., et al.
Publicado: (2016)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
por: Wu, Kai-Jie, et al.
Publicado: (2018)

The slope associated with nadir prostate‐specific antigen is prognostically significant in men with hormone‐sensitive prostate cancer after primary androgen deprivation therapy
por: Zhenhao, Zeng, et al.
Publicado: (2022)

Comparison  of  efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma
por: Lyu, Jiahua, et al.
Publicado: (2019)

Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review
por: Liu, Lei, et al.
Publicado: (2020)

Feasibility, Tolerance, and Quality of Life for Hypofractionation Versus Conventional Fractionation for Post-mastectomy Radiotherapy in Indian Patients
por: Malik, Deepika, et al.
Publicado: (2022)

The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy
por: Ishikawa, Hitoshi, et al.
Publicado: (2020)

The leucocyte nadir, a predictor of chemotherapy efficacy?
por: Kvinnsland, S
Publicado: (1999)

Reaching the Nadir of Medication Overuse in Chronic Migraine
por: Onan, Dilara, et al.
Publicado: (2022)

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation
por: Geara, Fady B., et al.
Publicado: (2017)

Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions
por: Jiang, Huayong, et al.
Publicado: (2021)

Hypofractionated Prostate Radiotherapy with or without Conventionally Fractionated Nodal Irradiation: Clinical Toxicity Observations and Retrospective Daily Dosimetry
por: McDonald, Andrew M., et al.
Publicado: (2012)

Comparison of radiation dermatitis between hypofractionated and conventionally fractionated postoperative radiotherapy: objective, longitudinal assessment of skin color
por: Yamazaki, Hideya, et al.
Publicado: (2018)

A Dosimetric Comparison between Conventional Fractionated and Hypofractionated Image-guided Radiation Therapies for Localized Prostate Cancer
por: Li, Ming, et al.
Publicado: (2016)

Moderately Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Prostate Cancer: A Comparative Study with Conventionally Fractionated Radiation
por: Cante, Domenico, et al.
Publicado: (2020)

Dosimetric Comparison of Ultra-Hypofractionated and Conventionally Fractionated Radiation Therapy Boosts for Patients with High-Risk Prostate Cancer
por: Piotrowski, Tomasz, et al.
Publicado: (2022)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment
por: Koka, Krishna, et al.
Publicado: (2022)

Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis
por: Kovarik, Josef, et al.
Publicado: (2022)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
por: Ayoub, Zeina, et al.
Publicado: (2022)

Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial
por: Mendez, Lucas C., et al.
Publicado: (2020)

Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer
por: Yang, Jing, et al.
Publicado: (2021)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy
por: Chapman, Christopher H, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1ne0gmlj1j42crkp0fk5h3ee8p